Potential inheritance patterns of a prothrombin gene mutation in a 23-year-old female and ethical considerations of a positive diagnosis: a case report

Authors

  • Hannah Brand University of Pittsburgh, School of Dental Medicine

DOI:

https://doi.org/10.5195/d3000.2017.69

Keywords:

Prothrombin, mutation, hereditary hemophilia, clotting factor, bleeding disorder

Abstract

Background: Prothrombin, also called Factor II, is a blood clotting protein found in all individuals that is necessary to form blood clots. In most individuals, a balance between bleeding and blood clot formation occurs. However, in individuals with a mutation in the prothrombin gene, the balance is disrupted due to excess production of prothrombin which leads to an increase in blood clot formation (1). Inherited predispositions to blood clot formation are termed hereditary thrombophilia. Prothrombin G20210A mutations are one of the most common hereditary gene associations. Case Description: This report examines the case of a 23-year-old female who has tested positive for the prothrombin gene mutation. The individual has an extensive history of blood clots including 8 deep vein thromboses (DVTs), 4 pulmonary embolisms with one complete infarction, 4 superficial clots, and a miscarried pregnancy attributed to her thrombophilia. The individual has a significant family history of the mutation and takes Coumadin daily for prevention of further clots. Practical and Ethical Implications: Despite a strong familial history of blood clots and related hospitalizations, the parents of the case individual do not want to get their other children tested for the mutation for fear that the children will be denied insurance coverage in their futures. The case individual will likely continue to be on blood thinners indefinitely. This will affect many aspects of her life, including dental treatment, as she will be at an increased risk for bleeding.

References

Prothrombin 20210 Mutation (Factor II Mutation); Varga EA, Moll S; Circulation; 2004, July;110(3):e15-8. PMID: 15262854.

Yagiela, Dowd, Johnson, et al (2011) Pharmacology and Therapeutics for Dentistry. St. Louis: Mosby Elsevier. 504 p.

Lentz, SR; University of Iowa Hospitals and Clinics; 2005. [cited 2017 Mar 15]. Availa-ble from https://www.healthcare.uiowa.edu/labs/lentz/Information_For_Patients/PDF/Prothrom-bin%20Gene%20Mutation%20Brochure.pdf

Homozygotes for prothrom-bin gene 20210 A allele in a thrombophilic family without clinical manifestations of ve-nous thromboembolism; Sou-to JC, Mateo J, Soria JM, et al.; Haematologica; 1999; 84(7):627-32. PMID: 10406905.

Genetics Home Reference; National Institute of Health; U.S. National Library of Medi-cine; 2008. [cited 2017 Mar 26]. Available from

https://ghr.nlm.nih.gov/condition/prothrombin-thrombophilia#inheritance

Anticoagulants; The Johns Hopkins Lupus Center; 2017. [cited 2017 Mar 26]. Availa-ble from https://www.hopkinslupus.org/lupus-treatment/common-medications-conditions/anticoagulants/

Anticoagulant and Antiplate-let Medications and Dental Procedures; The American Dental Association; 2015. [cited 2017 Mar 28] Available from http://www.ada.org/en/member-center/oral-health-topics/anticoagulant-antiplatelet-medications-and-dental-

Genetic Information Nondis-crimination Act; U.S. Depart-ment of Health and Human Services; 2017. [cited 2017 Mar 28]. Available from https://www.hhs.gov/hipaa/for-professionals/special-topics/genetic-information/index.html

Downloads

Published

2017-06-14

Issue

Vol 5, No 1 (2017)

Section

Adults & the Elderly

License

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Revised 7/16/2018. Revision Description: Removed outdated link.